I
Isabel Syndikus
Researcher at Clatterbridge Cancer Centre NHS Foundation Trust
Publications - 101
Citations - 9504
Isabel Syndikus is an academic researcher from Clatterbridge Cancer Centre NHS Foundation Trust. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 30, co-authored 84 publications receiving 7251 citations. Previous affiliations of Isabel Syndikus include BC Cancer Agency & The Royal Marsden NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris Parker,Sten Nilsson,Sten Nilsson,D. Heinrich,Svein Inge Helle,Joe M. O'Sullivan,Sophie D. Fosså,Ales Chodacki,Paweł Wiechno,John P Logue,Mihalj Seke,Anders Widmark,D. C. Johannessen,Peter Hoskin,David Bottomley,Nicholas D. James,Arne Solberg,Isabel Syndikus,Ján Kliment,S. Wedel,S. Boehmer,Marcos F. Dall'Oglio,Lars Franzén,Robert E. Coleman,Nicholas J. Vogelzang,C.G. O'Bryan-Tear,K. Staudacher,J. Garcia-Vargas,M. Shan,Øyvind S. Bruland,Oliver Sartor +30 more
TL;DR: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival and was associated with low myelosuppression rates and fewer adverse events.
Journal ArticleDOI
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
David P. Dearnaley,Matthew R. Sydes,John Graham,Edwin Aird,David Bottomley,Richard A Cowan,Robert Huddart,Chakiath C Jose,John H L Matthews,Jeremy Millar,A. Rollo Moore,Rachel C Morgan,J. Martin Russell,Christopher D Scrase,Richard Stephens,Isabel Syndikus,Mahesh K. B. Parmar +16 more
TL;DR: The first analyses of effectiveness from the MRC RT01 randomised controlled trial are presented, finding Escalated-dose CFRT with neoadjuvant androgen suppression seems clinically worthwhile in terms of bPFS, progression-free survival, and decreased use of salvage androgens suppression.
Journal ArticleDOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
TL;DR: Hypofractionated radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy in 37 fractions and is recommended as a new standard of care for external-beam radiotherapy of localised prostate cancer after 5 years follow-up.
Journal ArticleDOI
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
A.M. Brunt,A.M. Brunt,Joanne S Haviland,Duncan Wheatley,Mark A Sydenham,Abdulla Alhasso,David J Bloomfield,Charlie Chan,Mark Churn,Susan Cleator,Charlotte E. Coles,Andrew Goodman,Adrian Harnett,Penelope Hopwood,Anna M. Kirby,Cliona C. Kirwan,Carolyn Morris,Zohal Nabi,Elinor J. Sawyer,Navita Somaiah,Liba Stones,Isabel Syndikus,Judith M Bliss,John Yarnold,Anne C Armstrong,Judith Bliss,D. Bloomfield,Jo Bowen,Murray Brunt,Hannah Chantler,C. Coles,Ellen M. Donovan,Andy Goodman,Susan Griffin,Jo Haviland,Penny Hopwood,Anna Kirby,Julie Kirk,C C Kirwan,Marjory MacLennan,Mark Sculphur,Judith Sinclair,M. Sydenham,Jean Tremlett,K Venables,Duncan Wheatley,J.R. Yarnold +46 more
TL;DR: 26 Gy in five fractions over 1 week is non-inferior to the standard of 40 Gy in 15 fractions over 3 weeks for local tumour control, and is as safe in terms of normal tissue effects up to 5 years for patients prescribed adjuvant local radiotherapy after primary surgery for early-stage breast cancer.
Journal ArticleDOI
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver Sartor,Robert E. Coleman,Sten Nilsson,Daniel Heinrich,Svein Inge Helle,Joe M. O'Sullivan,Sophie D. Fosså,Ales Chodacki,Paweł Wiechno,John P Logue,Anders Widmark,Dag Clement Johannessen,Peter Hoskin,Nicholas D. James,Arne Solberg,Isabel Syndikus,Nicholas J. Vogelzang,C. Gillies O'Bryan-Tear,M. Shan,Øyvind S. Bruland,Chris Parker +20 more
TL;DR: Radium-223 treatment did not seem to significantly reduce the risk of symptomatic pathological bone fracture, or the need for tumour-related orthopaedic surgical intervention, but should be considered as a treatment option for patients with castration-resistant prostate cancer and symptomatic bone metastases.